Pharmaceutical Firms and the Transition to Biotechnology: A Study in Strategic Innovation
- 1 January 1998
- journal article
- Published by Cambridge University Press (CUP) in Business History Review
- Vol. 72 (2), 250-278
- https://doi.org/10.2307/3116278
Abstract
During the twentieth century, the pharmaceutical industry experienced a series of dramatic changes as developments in science and technology generated new opportunities for innovation. Each of these transitions forced existing firms to develop new capabilities. The authors examine the most recent such transition, the shift to molecular genetics and recombinant DNA technology (1970 to the present), and explain how and why this transformation differed from the previous ones in pharmaceuticals. Small biotech startups played an important role in this transition, and the large pharmaceutical firms that began to enter the field had to develop new strategies for innovation. Two major strategies were adopted by the early movers, all of which created various kinds of alliances with the small biotech businesses. By the mid-1990s, the leading pharmaceutical manufacturers had established significant capabilities in the new field, but they were continuing to work with specialized biotechs in order to innovate across a broad range of therapeutic categories.Keywords
This publication has 49 references indexed in Scilit:
- The pharmaceutical industry in the twentieth century: A reappraisal of the sources of innovationHistory and Technology, 1996
- The changing dynamics of strategic alliances between US biotechnology firms and Japanese corporations and universitiesTrends in Biotechnology, 1994
- The Evolution of Integrative Capability: Innovation in Cardiovascular Drug DiscoveryIndustrial and Corporate Change, 1994
- Biotechnology in the drug discovery process: Strategic and management issuesMedicinal Research Reviews, 1993
- US biotechnology unitedTrends in Biotechnology, 1993
- Bioinformatics in Europe — The federation strikes backTrends in Biotechnology, 1993
- Biotechnology and the Pharmaceutical IndustryCancer Investigation, 1993
- Architectural Innovation: The Reconfiguration of Existing Product Technologies and the Failure of Established FirmsAdministrative Science Quarterly, 1990
- Technology transfer: an assessment of the major institutional vehicles for diffusion of U.S. biotechnologyTechnovation, 1989
- The Manipulation of GenesScientific American, 1975